Close Menu

NEW YORK – Ares Genetics, a Curetis Group company, will collaborate with BGI Group to make molecular tests for coronavirus 2019-nCoV available in Europe.

Ares will launch a next-generation sequencing testing service for the virus using BGI reagents. The firm will also collaborate, along with Curetis and BGI, in the distribution of NGS and PCR testing kits.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.